There has been a lot of buzz about the drug TXA (tranexamic acid), an inexpensive medication that has few negative side effects and has shown some success in reducing mortality in a segment of trauma patients.

But the key word is “effect.” Is TXA effective and is it being shown as having an effective benefit for prehospital trauma patients?

Join JEMS Editor Emeritus A.J. Heightman and the principals of the International Prehospital Medicine Institute (IPHMI): Will Chapleau, EMT-P, RN, TNS; Greg Chapman, B.S., R.R.T., REMT-P; Michael J. Hunter, EMT-P, TP-C; Peter T. Pons, M.D., F.A.C.E.P.; and Lance Stuke, M.D., F.A.C.S, as they discuss TXA, its indications and a whole host of relevant research such as the large CRASH-2 trials, the Military (MATTERS) study; the civilian prehospital and hospital “STAAMP” study and the CRASH-3 Traumatic Brain injury study.

The content and discussion will help you understand what the research is showing and whether TXA has a future in the field of prehospital medicine.